Discover how Inotiv rederived multiple cell lines
Cell lines are often initially developed quickly to answer research questions. But as these short-term projects turn into commercially viable cell lines, their production yield may be compromised.
In this case study, you will see how Inotiv used its expertise and resources to optimize 55 different cells lines to meet production goals and enable high-quality manufacture.
Along the way, the team had to overcome micro-plasma contaminated cell lines, and rederive low yield cell lines up to 100% secretion in readiness for production-level testing.
Download your copy and learn
- Understand how a personalized oncology medicine developer ended up with poor cell lines
- Discover how Envigo took poor hybridoma cell lines from 5% secretion to 100% secretion
- Gain insights into the process undertaken to clean and rederive 55 separate cell lines to production quantity readiness
